Immunovant Inc
IMVT
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.15B
Close$
$4.94
87.2% downside
Current Fair Value
87.2% downsideOvervalued by 87.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.15 Billion |
|---|---|
| Enterprise Value | $7.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.77 |
| Beta | 0.77 |
| Outstanding Shares | 203,709,320 |
Return
| Return on Equity | -59.30% |
|---|---|
| Return on Assets | -52.83% |
| Return on Invested Capital | -48.21% |
Valuation & Multiples
| P/E Ratio | -14.28 |
|---|---|
| PEG | -36.72 |
| Price to Sales | - |
| Price to Book Ratio | 9.69 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -17.64 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 4, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 10.46% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.09%▼ 60.84% |
|---|---|
| Total Invested | $7.27M▼ 99.74% |
| Investors Holding | 8▼ 218.00% |
ESG Score
No data